ECCT Premium Event

Tackling Atherosclerotic Cardiovascular Disease in Taiwan
台灣ASCVD心臟疾病報告書發表會

Guest speakers

• Dr Renae Beardmore, Founder, Evohealth (pre-recording)

Panellists

• Wu Chao-Chun, Director General, Health Promotion Administration (invited) 衛生福利部國民健康署吳昭軍署長（已邀請）
• Shih Chung-Liang, Director General, National Health Insurance Administration (invited) 衛生福利部中央健康保險署石崇良署長（已邀請）
• Ms Fran Milnes, Novartis Taiwan President 台灣諾華總裁麥芳蘭女士

Moderator

• Dr Li Yi-Heng, Senior Attending Physician of the Division of Cardiology, National Cheng Kung University Hospital
  國立成功大學醫學院內科部及內科學科 李貽恒教授

This event will be conducted in Chinese. English interpretation will be offered on site.

Date & Time: 12:00 – 14:00, Tuesday, 25 April 2023
Venue: Ballroom B, 3F, Regent Taipei / 台北晶華酒店3F 宴會廳 B
Address: No. 3, Ln. 39, Sec. 2 ZhongShan N. Rd., Taipei 104, Taiwan / 104台北市中山區中山北路二段39巷3號

Cardiovascular disease (CVD) is a leading cause of death and disability, accounting for almost one third of all deaths worldwide. Atherosclerotic cardiovascular disease (ASCVD) is a major contributor to the burden of CVD, accounting for an estimated 85% of cases globally. Yet when identified early, up to 90% of CVD deaths are preventable. ASCVD is an important public health priority in Taiwan, with 40% people at risk of developing this life-threatening disease. The European Society of Cardiology identifies four modifiable risk factors for ASCVD – all of which are highly prevalent in Taiwan:

• Hyperlipidemia (high cholesterol) affects 44-58% of Taiwanese people.
• Hypertension (high blood pressure) affects 25% of Taiwanese people.
• Diabetes affects 10.3% of Taiwanese people.
• 13.1% of Taiwanese people are regular smokers.

This event is the forum for the official release of the report “Atherosclerotic cardiovascular disease in Taiwan: A public health priority” by Evohealth in cooperation with the ECCT. The report has been commissioned by Novartis International AG to develop a range of population health solutions to address the CVD burden in Taiwan. At the event, guest speakers will present an overview of the report, which explains the modifiable ASCVD risk factors and sets out population health recommendations to address ASCVD. The event will also feature a panel discussion involving healthcare experts from government and industry.

心血管疾病是全球死亡及失能的頭號原因，約佔全球每年死亡人數三分之一，並在過去十年持續高居台灣第二大死因。而心血管疾病中，又以動脈粥狀硬化疾病(ASCVD) 導致多數的疾病負擔，是與動脈中的膽固醇斑塊長期堆積有關，進而增加心肌梗塞、中風等心血管事件的風險，嚴重的疾病與失能除了造成醫療資源的耗用，還會帶來生產力損失等間接經濟成本。歐洲心臟學會確立的四項可控制ASCVD風險因子，在台灣皆高度盛行，且大多數可逆轉：

• 台灣44%至58%的人口患有高血脂
• 台灣25%人口患有高血壓
• 台灣3%的人口患有糖尿病
• 台灣1%的人口長期吸菸

歐洲商會擬於4月25日與諾華公司共同發表ASCVD心臟疾病台灣報告書。這份針對台灣ASCVD的專案報告，透過資料分析、專家訪談與經濟模型模擬，探討目前疾病現況與障礙，並提出六大建議，呼應WHO所強調，若能早期發現、早期治療，90%心血管疾病死亡是可預防的。本活動將邀請政府、醫界及產業界領袖，探討如何凝聚各界力量，互相合作、強化並加速心臟疾病的防治工作，共同確保台灣醫療體系與社會經濟之永續發展。

About the speakers

Dr Renae Beardmore is the founder of Evohealth, a health focused advisory firm. She is an experienced advisor to the health sector with thirty years of experience in health, covering the spectrum of healthcare from policy development, regulation and reimbursement through to clinical delivery. Her work is focused on ensuring that the system supports equitable patient access to care. She has held roles within the Australian Government and was responsible for the primary carriage of price negotiations for the national Pharmaceutical Benefits Scheme (PBS). She has also held the role of Chief Pharmacist for the Australian Capital Territory (ACT) and a member of the Australian Committee for Medicines Scheduling (ACMS) of the Therapeutic Goods Administration. She was the previous National Vice-President of the Pharmaceutical Society of Australia and has been appointed by the Federal Minister for Health to Chair the Pharmaceutical Services Federal Committee of Inquiry.

Dr Li Yi-Heng is a senior attending physician of the Division of Cardiology at National Cheng Kung University Hospital in Tainan, Taiwan, where he is also a professor and head of the Department of Internal Medicine in the University’s College of Medicine. Dr Li earned his medical degree from Kaohsiung Medical University and his PhD from the Graduate Institute of Basic Medical Science at National Cheng Kung University. He received cardiology fellowship training in the National Taiwan University Hospital in Taipei, Taiwan and completed a research fellowship in the Department of Cardiovascular Sciences and the Debakey Heart Center at Baylor College of Medicine in Houston, Texas, USA. Dr Li is a fellow of the European Society of Cardiology (FESC) and the American College of Cardiology (FACC). Dr Li has published more than 200 research papers and presented abstracts at more than 200 professional international medical events on subjects including the management of acute coronary syndromes, lipids and atherothrombosis.

About Evohealth

Evohealth brings deep sector expertise to support clients to deliver better health outcomes for patients. Evohealth works across the field of health with projects in public health, primary care, mental health, aged care and the Life Sciences Sector.

The event is co-branding with:

Cost: NT$1,600 for members and NT$2,400 for members' guest(s)

NT$15,000 per table of ten persons for member’s guest(s)

To cancel without penalty, written cancellations must be received 24 hours prior to the event.

Contact: Ivy Lin Tel: 2740-0236 ext. 228 / ivy.lin@ecct.com.tw